Oligonucleotide Ligation Assay (OLA) Resistance Study (OLA)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01898754
Recruitment Status : Completed
First Posted : July 12, 2013
Last Update Posted : November 6, 2017
Seattle Children's Hospital
University of Nairobi
Information provided by (Responsible Party):
Michael Chung, University of Washington

July 9, 2013
July 12, 2013
November 6, 2017
May 2013
December 2016   (Final data collection date for primary outcome measure)
The overall difference in rates of virologic failure with OLA-guided ART vs. Standard of care [ Time Frame: 12 months ]
The primary endpoint will be a comparison of the rates of viral non-suppression >1000 copies/mL between study arms at 12 months
Same as current
Complete list of historical versions of study NCT01898754 on Archive Site
  • The difference in virologic failure among the subgroup of ARV-naïve participants with transmitted drug-resistance (TDR) associated with use of OLA-guided ART vs. SOC [ Time Frame: 15 months ]
  • The difference in virologic failure among the subgroup of participants referred to Hope Center with previous or ongoing ARV use associated with use of OLA-guided ART vs. SOC [ Time Frame: 15 months ]
  • Prevalence of TDR by consensus sequencing and OLA [ Time Frame: 15 months ]
  • Proportion of subgroup with TDR with virologic failure by randomization arm [ Time Frame: 15 months ]
  • Prevalence of TDR increase in the Coptic Clinic [ Time Frame: 15 months ]
  • Estimates of medical resource utilization during the one-year trial period [ Time Frame: 15 months ]
  • An assessment the short-term cost-effectiveness of OLA-guided testing [ Time Frame: 15 months ]
  • An assessment of the potential long-term cost-effectiveness of OLA-guided testing over a patient's lifetime [ Time Frame: 15 months ]
  • Determination of whether low-level ARV resistance (<5%) detected by PYRO but not by OLA is associated with virologic failure [ Time Frame: 15 months ]
Same as current
  • Descriptions of technology transfer of OLA to the Hope Center Laboratory, including intra- and inter-assay the reproducibility, and discussion of obstacles and possible solutions [ Time Frame: 15 months ]
  • A comparison of OLA results obtained using DBS in Kenya to retesting of same specimens with input of viral templates measured in Seattle [ Time Frame: 15 months ]
  • A comparison of rates of resistance detected across codons by OLA vs. consensus sequencing in Seattle [ Time Frame: 15 months ]
Same as current
Oligonucleotide Ligation Assay (OLA) Resistance Study
Drug-resistance Testing in Kenya to Improve ART Suppression of HIV Replication
The investigators propose to gauge improvements in the rate of durable suppression of viral replication by ART when OLA is used to guide clinical decisions at the PEPFAR Coptic Hope Center in Kenya, and to determine the cost-effectiveness of implementing this strategy at Coptic Hope Center.

Durable suppression of HIV replication is critical to (1) improving the health of infected individuals, (2) to reducing HIV transmission to sexual partners and from mothers to their infants, and (3) to maintaining the effectiveness of the current 1st-line non-nucleoside reverse transcriptase inhibitors (NNRTI)- based ART. Across multiple trials, individuals with NNRTI-resistance, even at low-concentrations, have substantially greater virologic failure when treated with NVP- vs PI-ART. A cost-effective strategy is needed to detect and manage ARV-resistant HIV infections. A simple low-cost innovative assay the investigators developed and successfully transferred to Asian and African countries (oligonucleotide ligation assay (OLA)) can detect NNRTI+lamivudine (3TC) resistant HIV using reagents that costs <$7.00/person. Furthermore, detection of NNRTI-resistance by OLA is highly (P<0.001) associated with virologic failure of nevirapine (NVP)-ART in two retrospective studies; one of Thai women who had been previously randomized to single-dose NVP and the second of ARV-naïve Kenyan adults.

The investigators hypothesize that implementation of OLA into routine care will allow Kenyan clinicians to appropriately target protease inhibitor (PI)-based ART and improve rates of durable suppression of viral replication, and thus improve CD4 cell gains and individuals' health, reduce the transmission of ARV-resistant HIV within the community, and maintain the utility of NNRTI-ART. In addition, the investigators hypothesize that programmatically OLA-guided ART will be more cost-efficient compared to the current strategy of empiric use of NNRTI-ART as initial treatment.

Not Applicable
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
HIV Positive
Other: Pre-ART Oligonucleotide Assay (OLA)
Block randomization (1:1) to pre-ART OLA testing or OLA testing after 12mo on ART
Other Name: Pre-ART OLA
  • Experimental: Pre-ART Oligonucleotide Assay (OLA)
    Pre-ART OLA will be tested for resistance at 5 pol codons conferring high-level resistance to NNRTI and 3TC (K103N, V106M, Y181C, G190A and M184V)
    Intervention: Other: Pre-ART Oligonucleotide Assay (OLA)
  • No Intervention: No OLA (Standard of Care [SOC])
    The participants will receive standard of care as per Kenya guidelines but will be offered OLA resistance testing after 12 months
Silverman RA, Beck IA, Kiptinness C, Levine M, Milne R, McGrath CJ, Bii S, Richardson BA, John-Stewart G, Chohan B, Sakr SR, Kiarie JN, Frenkel LM, Chung MH. Prevalence of Pre-antiretroviral-Treatment Drug Resistance by Gender, Age, and Other Factors in HIV-Infected Individuals Initiating Therapy in Kenya, 2013-2014. J Infect Dis. 2017 Dec 19;216(12):1569-1578. doi: 10.1093/infdis/jix544.

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
February 2017
December 2016   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Confirmed HIV infection
  2. >2 years of age
  3. Qualifying for 1st-line ART based on Kenyan Guidelines
  4. Plan to reside in area for >1 year
  5. Adult patient or parent of minor agrees to study and provides informed consent

Exclusion Criteria:

  1. Received ART previously from Hope Center
  2. Ongoing ART
  3. Plan to start 2nd-line ART
Sexes Eligible for Study: All
2 Years and older   (Child, Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Plan to Share IPD: No
Michael Chung, University of Washington
University of Washington
  • Seattle Children's Hospital
  • University of Nairobi
Principal Investigator: Lisa Frenkel, MD University of Washington, Seattle Children's Research Institute
Principal Investigator: Michael H Chung, MD, MPH Department of Global Health, University of Washington
University of Washington
November 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP